@article{26c65a502739448391fdc3bd8df4192d,
title = "Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis",
abstract = "Rabies immune globulin (RIG) is essential for post-exposure prophylaxis but is expensive and not widely available. Rabies virus-neutralizing human monoclonal antibodies (Mabs) were evaluated in vitro and in a Syrian hamster model as a potential future alternative. Seven Mabs neutralized representative rabies virus variants. However, a European bat lyssavirus was not neutralized by either Mabs or RIG. Moreover, Duvenhage virus was neutralized by RIG, but not by Mabs, and Lagos bat and Mokola viruses were neutralized by one Mab but not by RIG. In hamsters, one Mab resulted in protection that was comparable to human RIG. These results suggest that Mabs may provide a promising alternative to RIG.",
keywords = "Human monoclonal antibodies, Lyssaviruses, Rabies",
author = "Hanlon, {C. A.} and DeMattos, {C. A.} and DeMattos, {C. C.} and M. Niezgoda and Hooper, {D. C.} and H. Koprowski and A. Notkins and Rupprecht, {C. E.}",
note = "Funding Information: The authors would like to thank John Shaddock, Pamela Yager, Jean Smith, and other staff of the Rabies Section, the Viral and Rickettsial Zoonoses Branch and the Animal Resources Branch at the CDC for expert technical assistance, as well as the CSIRO Division of Animal Health, Geelong, Australia, and various USA state health departments, particularly in Alabama, California and Texas, for contribution of specimens for rabies virus variant identification and virus challenge. In addition, the authors would like to thank Jean M. Champion, Rhonda B. Kean and other personnel of the Thomas Jefferson University, Centre for Neurovirology, for their substantial efforts in the production and purification of the antibodies. Funding for these studies were provided in part by RFP NIH-NIDR-2-95-6R. These studies were conducted under the Thomas Jefferson University human subjects committee IRB control number 95.0978 and the University Compliance number M1115.",
year = "2001",
month = jul,
day = "16",
doi = "10.1016/S0264-410X(01)00135-9",
language = "English",
volume = "19",
pages = "3834--3842",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "28-29",
}